Therapeutic approaches aimed at these axes, such as fucosylated glycan mimetics to reinstate Fut2-mediated symbiosis or microbiota transplantation to rectify MyD88-associated communities, show potential for IBD and metabolic disorders, highlighting that intestinal immune genetics serve as principal regulators of microbial community. Here, MYD88 is linked to Other metabolic disease.